EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19)

Alfredo Addeo, Daniel Dietrich, Nicolas Mach, Michael Thomas Mark, Markus Joerger, Patrizia Froesch, Martina Imbimbo, David König, Eugenio Fernandez, Annalea Patzen, Hansjörg Vees, Cristina Picardi und 1 weitere

European Journal of Cancer · 2026-01 · 232 · 116138

DOI: 10.1016/j.ejca.2025.116138 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-01. Verfasst von Alfredo Addeo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Service, University Hospital Geneva, Switzerland. Electronic address: alfredo.addeo@hug.ch. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyHumansCarboplatinFemaleMaleEtoposideMiddle AgedAgedAntibodies, MonoclonalAdultProspective StudiesNeoplasm StagingProgression-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

ImmunotherapySCLCThoracic radiotherapy

Substanzen

durvalumabCarboplatinEtoposideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Oncology Service, University Hospital Geneva, Switzerland. Electronic address: alfredo.addeo@hug.ch.
  • Swiss Group for Clinical Cancer Research (SAKK), Competence Center, Bern, Switzerland.
  • Oncology Service, University Hospital Geneva, Switzerland.
  • Department of Hematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland; Faculty of Biomedical Sciences, Universita della Svizzera Italiana, Lugano, Switzerland.
  • Department Medical Oncology/Hematology, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Förderung

  • AstraZeneca PLC

Zitieren

APA

Addeo, A., Dietrich, D., Mach, N., Mark, M. T., Joerger, M., Froesch, P., Imbimbo, M., König, D., Fernandez, E., Patzen, A., Vees, H., Picardi, C., & Früh, M. (2026). Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19). European Journal of Cancer, 232, 116138. https://doi.org/10.1016/j.ejca.2025.116138

Vancouver

Addeo A, Dietrich D, Mach N, Mark MT, Joerger M, Froesch P, et al. Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19). European Journal of Cancer. 2026;232:116138. doi:10.1016/j.ejca.2025.116138

BibTeX
@article{Addeo2026,
  author = {Addeo, Alfredo and Dietrich, Daniel and Mach, Nicolas and Mark, Michael Thomas and Joerger, Markus and Froesch, Patrizia and Imbimbo, Martina and König, David and Fernandez, Eugenio and Patzen, Annalea and Vees, Hansjörg and Picardi, Cristina and Früh, Martin},
  title = {Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19)},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {232},
  pages = {116138},
  doi = {10.1016/j.ejca.2025.116138}
}
Kostenlos starten →